Enjaymo (sutimlimab-jome) rapidly and sustainably reduces red blood cell destruction and the need for blood transfusions in most adults with hard-to-treat cold agglutinin disease (CAD) in real-world clinical settings, a study showed. “[Enjaymo] demonstrated rapid, durable effectiveness and a favorable safety profile in heavily pretreated real-world CAD patients,”…